31127-40-9

Usage

Uses

Used in Pharmaceutical Industry:
6-(azidomethyl)-2,3-dihydrobenzo[b][1,4]dioxine hydrochloride is used as a synthetic reagent for the preparation of complex organic molecules, such as 4-(4-hydroxy-3,5-dimethoxyphenyl)-6,7-dimethoxy-dihydroisoquinolin-3-one. This application is significant because the target molecule has potential therapeutic properties, which can be further explored for the development of new drugs.
Used in Chemical Synthesis:
In the field of chemical synthesis, 6-(azidomethyl)-2,3-dihydrobenzo[b][1,4]dioxine hydrochloride serves as a versatile building block for creating a wide range of chemical compounds. Its unique structure allows for various functional group transformations, making it a valuable asset in the synthesis of novel molecules with potential applications in different industries.

Upstream product

• 31127-39-6 2,3-dihydrobenzo[b][1,4]dioxin-6-carbaldoxime 
• 29668-44-8 2,3-dihydro-benzo[1,4]dioxin-6-carbaldehyde 
• 17413-10-4 2,3-dihydro-1,4-benzodioxin-6-ylmethylamine 

Downstream Products

• 1175086-06-2 (2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-[1-(3-iodo-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amine 
• 1175086-30-2 (2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-[1-(3,5-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine 

Relevant academic research and scientific papers

Reusable Nickel Nanoparticles-Catalyzed Reductive Amination for Selective Synthesis of Primary Amines

The preparation of nickel nanoparticles as efficient reductive amination catalysts by pyrolysis of in situ generated Ni-tartaric acid complex on silica is presented. The resulting stable and reusable Ni-nanocatalyst enables the synthesis of functionalized and structurally diverse primary benzylic, heterocyclic and aliphatic amines starting from inexpensive and readily available carbonyl compounds and ammonia in presence of molecular hydrogen. Applying this Ni-based amination protocol, -NH2 moiety can be introduced in structurally complex compounds, for example, steroid derivatives and pharmaceuticals.

Efficient hydrogenation of benzaldoximes and Schiff bases on ceramic high-porosity palladium catalysts

An efficient catalytic method for the synthesis of benzyl- and dibenzylamines by hydrogenating oximes and Schiffbases was developed on palladium supported high-porosity foamed ceramic block catalyst. The multiple regeneration ability of the foamed ceramic block catalyst can significantly decrease the Pd consumption as compared to the use of the conventional 10%Pd/C catalyst. Owing to a high hardness of the foamed ceramic catalyst, the reaction mixture can rapidly be removed from the reactor without using filtering devices. The structures produced by the reaction are fragments of biologically active and natural molecules. Antiproliferative properties of dibenzylamines revealed on the sea urchin embryo model suggest that these compounds can be considered as promising agents for the design of new anticancer drugs.

Sodium nitrite-catalyzed aerobic oxidative Csp2-Csp3 coupling: Direct construction of the 4-aryldihydroisoquinolinone moiety

A bioinspired approach for the construction of the 4- aryldihydroisoquinolinone moiety via direct oxidative Csp2-Csp 3 coupling has been developed, which uses inexpensive sodium nitrite as catalyst and environmentally benign oxygen in the air as terminal oxidant.

NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS

The invention relates to substituted pyrazolo[3,4-d]pyrimidine derivatives of the Formula-(I), or pharmaceutically acceptable salts thereof, which possess anti-proliferative activity such as anti-cancer activity and are accordingly useful in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of substituted pyrazolo[3,4-d]pyrimidine derivatives, to pharmaceutical compositions containing the compound and to its use in the manufacture of medicaments for the production of an anti-proliferative effect in a warm-blooded animal such as man

Anthranilic acid derivatives as inhibitors of the cGMP-phosphodiesterase

Compounds of formula (I) STR1where R 1 is hydrogen; R 2 is nitro, cyano or halo(lower)alkyl; R 3 is phenyl substituted with one or more substituents selected from halogen, cyano and lower alkoxy; A is a lower alkylene group; R 4 is a group CR 6 R 7 R 8 wherein R 6 and R 7 form, together with the carbon atom to which they are attached a cycloalkyl group optionally substituted with hydroxy, lower alkoxy or a lower alkanoylamino; and R 8 is hydrogen; its prodrug and a salt thereof.